Stock Events

Stock Events

Protagonist Therapeutics 

$105.86
23
+$0+0% Today

Statistics

Day High
105.86
Day Low
105.86
52W High
-
52W Low
-
Volume
10
Avg. Volume
-
Mkt Cap
6.75B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2025
Q4 2025
Next
-0.69
-0.62
-0.56
-0.49
Expected EPS
-0.488104
Actual EPS
N/A

Financials

-282.83%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
92.03MRevenue
-260.3MNet Income

Analyst Ratings

$106.67Average Price Target
The highest estimate is 125.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PTGX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Arvinas
ARVN
Mkt Cap744.45M
Arvinas is involved in the development of protein degradation therapeutics, a field that overlaps with Protagonist's work on peptide-based therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is focused on gene editing, competing in the broader biotech space for novel treatments, including cancer, which is a focus area for Protagonist.
Novartis
NVS
Mkt Cap297.32B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Protagonist is active, such as cancer.
AMGEN
AMGN
Mkt Cap187.56B
Amgen's focus on human therapeutics in areas including oncology and inflammation competes with Protagonist's therapeutic development.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences' extensive work in antiviral drugs and cancer therapies places it in direct competition with Protagonist's research and development efforts.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals' focus on developing monoclonal antibodies for a wide range of diseases competes with Protagonist's peptide-based therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals' work on treating serious diseases, including cancer, with novel drugs competes with Protagonist's development pipeline.

About

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Show more...
CEO
ISIN
US74366E1029

Listings

MX
MX
PTGX.MX
XNAS
US
PTGX
BOATS
BOATS
PTGX.BOATS

0 Comments

Share your thoughts

FAQ

What is Protagonist Therapeutics stock price today?▼
The current price of PTGX.BOATS is $105.86 USD — it has increased by +0% in the past 24 hours. Watch Protagonist Therapeutics stock price performance more closely on the chart.
What is Protagonist Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Protagonist Therapeutics stocks are traded under the ticker PTGX.BOATS.
What is Protagonist Therapeutics market cap?▼
Today Protagonist Therapeutics has the market capitalization of 6.75B
When is the next Protagonist Therapeutics earnings date?▼
Protagonist Therapeutics is going to release the next earnings report on May 06, 2026.
What were Protagonist Therapeutics earnings last quarter?▼
PTGX.BOATS earnings for the last quarter are -0.69 USD per share, whereas the estimation was -0.57 USD resulting in a -21.65% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protagonist Therapeutics revenue for the last year?▼
Protagonist Therapeutics revenue for the last year amounts to 92.03M USD.
What is Protagonist Therapeutics net income for the last year?▼
PTGX.BOATS net income for the last year is -260.3M USD.
When did Protagonist Therapeutics complete a stock split?▼
Protagonist Therapeutics has not had any recent stock splits.